AGBL3 and rheumatoid arthritis: Autoantibodies against CFFCP1, CFFCP2 and CFFCP3 showed a comparable sensitivity and specificity for RA to CCP2 and CCP3/CCP3.1 commercial tests and rendered better results in terms of identifying patients with poor radiographic outcomes [87,88].